Oncogene
Ohali, A., Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, 39 Jabotinski Street, Petah Tikva 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel
Avigad, S., Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, 39 Jabotinski Street, Petah Tikva 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Pediatric Hematology Oncology, S. Children's Med. Ctr. Israel, 14 Kaplan Street, Petah Tikva 49202, Israel, Laboratory of Molecular Oncology, Pediatric Hematology Oncology, S. Children's Med. Ctr. Israel, 14 Kaplan Street, Petah Tikva 49202, Israel
Zaizov, R., Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, 39 Jabotinski Street, Petah Tikva 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Pediatric Hematology Oncology, S. Children's Med. Ctr. Israel, 14 Kaplan Street, Petah Tikva 49202, Israel
Ophir, R., DNA Array Unit, Department of Biological Services, Weizmann Institute of Science, POB 26, Rehovot 76100, Israel
Horn-Saban, S., DNA Array Unit, Department of Biological Services, Weizmann Institute of Science, POB 26, Rehovot 76100, Israel
Cohen, I.J., Pediatric Hematology Oncology, S. Children's Med. Ctr. Israel, 14 Kaplan Street, Petah Tikva 49202, Israel
Meller, I., Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel
Kollender, Y., Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel
Issakov, J., Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel
Yaniv, I., Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, 39 Jabotinski Street, Petah Tikva 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Pediatric Hematology Oncology, S. Children's Med. Ctr. Israel, 14 Kaplan Street, Petah Tikva 49202, Israel
Ewing's sarcoma (ES) is the second most common primary malignant bone tumor in children and adolescents. Currently accepted clinical prognostic factors fail to classify ES patients' risk to relapse at diagnosis. We aimed to find a new strategy to distinguish between poor and good prognosis ES patients already at diagnosis. We analysed the gene expression profiles of 14 primary tumor specimens and six metastases from ES patients, using oligonucleotide microarray analysis. The over-expression of two genes was validated by quantitative PCR using the LightCycler system. We identified two distinct gene expression signatures distinguishing high-risk ES patients that are likely to progress from low-risk ES patients with a favorable prognosis of long-term progression-free survival. The microarray-based classification was superior to currently used prognostic parameters. Over-expressed genes in the poor prognosis patients included genes regulating the cell cycle and genes associated with invasion and metastasis, while among the downregulated genes were tumor suppressor genes and inducers of apoptosis. Our results indicate the existence of a specific gene expression signature of outcome in ES already at diagnosis, and provide a strategy to select patients who would benefit from risk-adapted improved therapy.
Powered by ClearMash Solutions Ltd -
Volcani treasures
About
Terms of use
Prediction of high risk Ewing's sarcoma by gene expression profiling
23
Ohali, A., Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, 39 Jabotinski Street, Petah Tikva 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel
Avigad, S., Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, 39 Jabotinski Street, Petah Tikva 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Pediatric Hematology Oncology, S. Children's Med. Ctr. Israel, 14 Kaplan Street, Petah Tikva 49202, Israel, Laboratory of Molecular Oncology, Pediatric Hematology Oncology, S. Children's Med. Ctr. Israel, 14 Kaplan Street, Petah Tikva 49202, Israel
Zaizov, R., Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, 39 Jabotinski Street, Petah Tikva 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Pediatric Hematology Oncology, S. Children's Med. Ctr. Israel, 14 Kaplan Street, Petah Tikva 49202, Israel
Ophir, R., DNA Array Unit, Department of Biological Services, Weizmann Institute of Science, POB 26, Rehovot 76100, Israel
Horn-Saban, S., DNA Array Unit, Department of Biological Services, Weizmann Institute of Science, POB 26, Rehovot 76100, Israel
Cohen, I.J., Pediatric Hematology Oncology, S. Children's Med. Ctr. Israel, 14 Kaplan Street, Petah Tikva 49202, Israel
Meller, I., Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel
Kollender, Y., Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel
Issakov, J., Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel
Yaniv, I., Molecular Oncology, Felsenstein Medical Research Center, Rabin Medical Campus, 39 Jabotinski Street, Petah Tikva 49100, Israel, Sackler Faculty of Medicine, Tel Aviv University, POB 39040, Tel Aviv 69978, Israel, Pediatric Hematology Oncology, S. Children's Med. Ctr. Israel, 14 Kaplan Street, Petah Tikva 49202, Israel
Prediction of high risk Ewing's sarcoma by gene expression profiling
Ewing's sarcoma (ES) is the second most common primary malignant bone tumor in children and adolescents. Currently accepted clinical prognostic factors fail to classify ES patients' risk to relapse at diagnosis. We aimed to find a new strategy to distinguish between poor and good prognosis ES patients already at diagnosis. We analysed the gene expression profiles of 14 primary tumor specimens and six metastases from ES patients, using oligonucleotide microarray analysis. The over-expression of two genes was validated by quantitative PCR using the LightCycler system. We identified two distinct gene expression signatures distinguishing high-risk ES patients that are likely to progress from low-risk ES patients with a favorable prognosis of long-term progression-free survival. The microarray-based classification was superior to currently used prognostic parameters. Over-expressed genes in the poor prognosis patients included genes regulating the cell cycle and genes associated with invasion and metastasis, while among the downregulated genes were tumor suppressor genes and inducers of apoptosis. Our results indicate the existence of a specific gene expression signature of outcome in ES already at diagnosis, and provide a strategy to select patients who would benefit from risk-adapted improved therapy.
Scientific Publication